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Abstract Clenbuterol screening of bovines is done by
analysis of urine, for monitoring living animals, and liver,
for monitoring animals after slaughter. ELISA has gener-
ally been used as the main method for these purposes.
Nevertheless, in Europe, methods must be validated
according to Commission Decision (EC) 657/2007 criteria,
i.e. by use of reference materials. Production of ‘‘in house’’
reference materials is a possibility, but the homogeneity,
storage temperature, and period of stability of these
materials must be investigated in the laboratory itself. This
paper reports GC–MS evaluation of an ‘‘in-house’’-pro-
duced batch of aliquots of bovine urine and liver, fortified
with 10.0 ng/ml and 10.0 ng/g clenbuterol, respectively,
and stored at -20 C and at -60 C. For urine stored for
20 weeks at -20 C and at 60 C the stability of clenbu-
terol was proved at the 95% confidence level. For liver,
however, it was demonstrated at the same confidence level
that clenbuterol was highly unstable during storage for
20 weeks at either of the temperatures studied.
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Introduction
The use of clenbuterol and other beta-agonists as growth
promoters in animal production is an illegal practice
throughout the EU [1, 2]. However, there have been some
reports of clenbuterol food contamination in several
European countries, including Spain [3, 4], France [5],
Italy [6–8], Portugal [9] and in China [10].
In order to implement measures to monitor the prohibi-
tion, legislative acts have been issued in the EU that have led
to the elaboration of residue-control plans for the collection
of samples and their laboratory analysis in all EU Member
States [1]. Bovine urine and liver were selected as matrices
for monitoring living and slaughtered animals, respectively.
Within this context, residue analysis laboratories gen-
erally follow a strategy that comprises two distinctive
steps—a first, screening, step, in which a large number of
samples are analysed with a method that guarantees a
minimum of false negatives, and a second, confirmation,
step in which samples that were positive in screening tests
are analysed by a method that makes it possible to identify
the molecular structure of the suspected substance. Both
screening and confirmatory methods of clenbuterol evalu-
ation must be validated according to procedures and
performance criteria that are common to all European
laboratories approved for official monitoring of residues, to
guarantee the quality and comparability of the analytical
results [1]. Method validation should be achieved by use of
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certified reference materials or, in their absence, by use of
blank samples spiked with a known concentration of the
substance under analysis, in order to determine the neces-
sary performance data, for example the method’s accuracy.
Until now, for analysis of clenbuterol in bovine urine and
liver, only the certified reference materials (CRM),
approved by the Community Bureau of Reference (BCR),
were available. These contain two beta-agonists (clenbu-
terol and salbutamol) for urine [11], and three beta-agonists
(clenbuterol, salbutamol and terbutaline) for liver [12].
ELISA (enzyme-linked immunosorbent assay) screening
tests for clenbuterol are capable of detecting more than one
beta-agonist simultaneously and cannot be validated using
these CRM, because ELISA methods give a result for the
total concentration of the various beta-agonists, each of
which has its own specific cross-reaction and recovery. For
this reason blank samples fortified with clenbuterol at
different concentrations are used in multidetection beta-
agonist screening tests in order to monitor the performance
of the method. However, using these spiked blank samples
for analysis does not enable deduction of whether the
observed variation is due solely to a particular day’s
recovery or whether it is also caused by random or sys-
tematic errors in the preparation of the spiked samples.
This doubt prevents trustworthy determination of the
mentioned performance data, which is mandatory for
method validation. Thus, the objective of this study was to
evaluate, by GC–MS, the possibility of producing ‘‘in
house’’ reference materials for ELISA screening, consist-
ing of urine and liver aliquots exogenously fortified with
clenbuterol.
Materials and methods
Reagents
Clenbuterol was purchased from Sigma (St Louis, MO,
USA). The internal standard (IS) used in GC–MS deter-
mination was hexa-deuterated clenbuterol (clenbuterol-D6)
supplied by RIVM (Bilthoven, The Netherlands). LiChro-
solv methanol (Merck, Darmstadt, Germany) was used as
solvent for preparation of standard solutions. The reagents
used in sample preparation and for obtaining and purifying
extracts of urine and liver were sodium acetate, monobasic
potassium phosphate, potassium hydroxide, 32% (w/w)
aqueous ammonia, glacial acetic acid, methanol, 37% (w/w)
hydrochloric acid, b-glucuronidase (30 U/ml) plus arylsul-
fatase (20 U/ml), all of which were acquired from Merck.
Ethyl acetate for chromatography (J.T. Baker, Deventer,
The Netherlands) was used for elution of the analyte. Solid-
phase extraction (SPE) columns containing 500 mg and
1000 mg (CleanScreen DAU, Bristol, USA) were used for
urine and liver, respectively. The reagents for sample
derivatization were MSTFA (N-methyl-N-trimethylsi-
lyltrifluoroacetamide) from Macherey–Nagel (Hoerdt,
Germany), TMIS (trimethyliodosilane) from Sigma, and
dithioerythritol from Merck.
Equipment
Beta-agonist-free bovine urine was homogenized on a
magnetic mixer (IKA Mag-Ret, Wilmington, USA). A
mixer cup (Kenwood A902, Havant, UK) was used for the
grinding and homogenization of beta-agonist-free liver. For
urine separation in 10.0 ml aliquots, a repetitive dispenser
of 10.0 ml ± 0.02 ml (Optifix, Main, DE) was used. For-
tified urine and liver were homogenized with a Reax 2000
vortex (Heidolph, Germany). Samples are stored at
-20 C ± 3 C in a freezer (Hausetec H410.144.0, Rome,
Italy); the temperature was monitored daily by means of a
Dr Friedrichs Max–Min thermometer (Berlin, Germany).
Storage at -60 C ± 10 C was done in an ultra-freezer
fitted with a permanent thermal record of temperature
(Revco, Asheville, USA). An ultracentrifuge (Beckman J2-
21M/E, Glenrothes, UK) was used for centrifugation and
SPE was undertaken with a vacuum system (J.T. Baker
SPE, Philipsburg, USA). Extracts were evaporated to dry-
ness with a Zymark (Hopkinton, USA) TurboVap-LV
sample-concentration system under a current of com-
pressed and dehydrated air supplied by a compressed air
pump with an air dehumidification system (Alpro
CS2000E, Germany). All pH adjustments were monitored
with a pH meter equipped with a combined glass electrode
coupled to a temperature probe (Metrohm, Herisau, Swit-
zerland). A heating block (Grants QBT2, Cambridge, UK)
and a Hewlett–Packard HP6890-HP5973 GC-MS system
acquired from Soquimica (Lisbon, Portugal) with a
HP-5MS chromatographic column (30.0 m 9 0.25 mm
ID 9 0.25 lm film thickness) were also used.
Origin of beta-agonist-free biological samples
The beta-agonist-free matrices used were samples of
bovine urine and liver analysed under the Azores Residue
Control Plan, provided by the Regional Veterinary Labo-
ratory of the Autonomous Region of the Azores (LRV) and
confirmed as free from clenbuterol by the Portuguese
Laboratory of Veterinary Investigation (LNIV), the
National Reference Laboratory for this group of residues
with CCa of 0.21 ng/ml and 0.45 ng/g, respectively for
urine and liver.
Standard solutions
Two 1000.0 ng/ml clenbuterol (work standard—WS) and
clenbuterol-D6 (internal work standard—IWS) solutions in
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methanol were prepared. These solutions were kept at
-20 C during the research period.
Preparation of beta-agonist-free bovine urine aliquots
and aliquots of bovine urine fortified with clenbuterol
The beta-agonist-free urine, frozen at -20 C, was thawed,
centrifuged (5000g, 20 min) and separated into aliquots of
10.0 ml. The aliquots needed for calibration curves were
stored at -20 C. Another fifty-four of these aliquots were
fortified with 100.0 ll WS. Fifty-four 10.0-ml aliquots
spiked with 10.0 ng/ml clenbuterol (UF aliquots) were thus
obtained, of which six aliquots (*11% of the batch) were
separated at random (aliquot numbers 6, 13, 24, 35, 47, 54)
and analysed on the same day (batch homogeneity study).
Twenty-four aliquots (aliquot numbers 1, 3, 5, 8, 10, 12, 15,
17, 19, 21, 23, 26, 28, 30, 32, 34, 37, 39, 41, 43, 45, 48, 50,
52) were stored at -20 C. Twenty-four aliquots (aliquot
numbers 2, 4, 7, 9, 11, 14, 16, 18, 20, 22, 25, 27, 29, 31, 33,
36, 38, 40, 42, 44, 46, 49, 51, 53) were stored at -60 C.
Preparation of beta-agonist-free bovine liver aliquots
and aliquots of bovine liver fortified with clenbuterol
The beta-agonist-free liver stored at -20 C was thawed,
ground, homogenized, and separated into aliquots of
10.0 g. The aliquots needed for the calibration curves were
stored at -20 C with no addition of clenbuterol. An
additional fifty-four aliquots were spiked with 100.0 ll
WS. Fifty-four 10.0-g aliquots of liver fortified with
10.0 ng/g clenbuterol (FF aliquots) were thus obtained, of
which six aliquots (*11% of the batch) were separated at
random (aliquot numbers 7, 14, 25, 36, 46, 53) and ana-
lysed on the same day (batch homogeneity study). Twenty-
four aliquots (aliquot numbers 1, 3, 5, 8, 10, 12, 15, 17, 19,
21, 23, 26, 28, 30, 32, 34, 37, 39, 41, 43, 45, 48, 50, 52)
were stored at -20 C; and 24 aliquots (aliquot numbers 2,
4, 6, 9, 11, 13, 16, 18, 20, 22, 24, 27, 29, 31, 33, 35, 38, 40,
42, 44, 47, 49, 51, 54) were stored at -60 C.
Stability tests
For the stability studies, in addition to the samples analysed
on the first day to study homogeneity, aliquots of each
batch stored during 4, 8, 12, 16, and 20 weeks at each
temperature were analysed in triplicate.
Analytical methodology
The analytical methodology used for determination
of clenbuterol in urine and liver was described previously
[9, 13]. A brief summary is given below.
Obtaining urine extracts
IWS (100.0 ll) was added to a 10.0-ml aliquot of urine to
obtain 10.0 ng/ml IS clenbuterol-D6. The pH was adjusted
to 5.2 ± 0.3 with glacial acetic acid and then 4.0 ml ace-
tate buffer, pH 5.2 ± 0.3, was added. The mixture was
incubated with 50.0 ll b-glucuronidase plus arylsulfatase
at 45 C overnight. After cooling, 5.0 ml phosphate buffer,
pH 6.0 ± 0.3, was added and the pH was readjusted to
6.0 ± 0.3 with 1.0 mol/l potassium hydroxide. The whole
sample was then centrifuged (5500g, 5 min, 10 C) and
decanted.
The analyte was purified on an SPE column previously
conditioned with 2.0 ml methanol, 2.0 ml water, and
2.0 ml phosphate buffer, pH 6.0 ± 0.3. The column con-
taining the retained analyte was then impregnated with
1.0 ml 1 mol/l acetic acid (10.0 min), submitted to a vac-
uum (-800 mbar/10 min), washed with 6.0 ml methanol,
again submitted to a vacuum (-800 mbar/10 min), and
then eluted with 6.0 ml 97:3 (v/v) ethyl acetate–aqueous
ammonia. The extract was evaporated to dryness at 45 C
under a current of dehydrated air [14].
Obtaining liver extracts
IWS (100.0 ll) was added to each 10.0-g aliquot of liver to
obtain 10.0 ng/g IS clenbuterol-D6. The sample was
ground and extracted in an Ultra-Turrax with addition of
20.0 ml acetate buffer, pH 5.2 ± 0.3. The mixture was
incubated with 50.0 ll b-glucuronidase plus arylsulfatase
at 45 C overnight. After cooling, the sample was
homogenized with hydrochloric acid (0.01 mol/l, 50.0 ml)
and the pH was readjusted to 6.0 ± 0.3. The sample was
then centrifuged (5000g, 30 min, 10 C), decanted, and the
supernatant was filtered.
The analyte was purified on an SPE column previously
conditioned with 4.0 ml methanol, 4.0 ml water, and
4.0 ml phosphate buffer, pH 6.0 ± 0.3. The column con-
taining the retained analyte was then impregnated with
2.0 ml 1.0 mol/l acetic acid (30 min), submitted to a vac-
uum (-800 mbar/10 min), washed with 12.0 ml methanol,
again submitted to a vacuum (-800 mbar/10 min), and
then eluted with 12.0 ml 97:3 (v/v) ethyl acetate–aqueous
ammonia. The extract was evaporated to dryness at 45 C
under a current of dehydrated air.
Derivatization of urine and liver extracts
The dry extracts of urine and liver were derivatized with
50.0 ll MSTFA–TMSI–dithioerythritol, 1000:2:2 (v/v/w)
at 60 C ± 3 C for 20 min [15].
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GC–MS
The derivatized extracts were injected in splitless mode for
1 min; the injection volume was 2.0 ll and the injector
temperature 270 C. The carrier gas was helium, flow rate
1.4 ml/min. The chromatographic oven temperature was
maintained at 100 C for 0.4 min then programmed at 10/
min to 200 C, which was maintained for 3 min, then
programmed at 10/min to 300 C which was maintained
5 min.
The interface temperature was 280 C and compounds
were detected in electron-impact (EI) mode, with an elec-
tron energy of 70 eV. Data were acquired by selective ion
monitoring (SIM) with ions of m/z 86, 300, 335 and 405
used for detection and identification of clenbuterol as the
trimethylsilyl derivative. For quantitative determination
ions of m/z 86 and 92 were used for clenbuterol and
clenbuterol-D6, respectively.
Results and discussion
Results from study of the homogeneity of the urine and
liver batches spiked with 10.0 ng/ml and 10.0 ng/g of
clenbuterol, respectively, indicate that each batch can be
considered homogeneous. Clenbuterol coefficients of var-
iation (CV) in spiked urine aliquots (2.3%) and liver
aliquots (3.7%) are not only very low but also much lower
than the admissible CV for intralaboratory repeatability
(between 16.0 and 21.0%, estimated through Horwitz’s
equation, for this concentration, as set down by Commis-
sion Decision (EC) 657/2002 [16]).
Data from studies of the stability of clenbuterol in
spiked urine and liver stored at either -20 C and -60 C
are presented in Fig. 1. Results from linear regression
analysis for each kind of sample at each one of the tem-
peratures studied, the mean concentration of clenbuterol,
and the respective coefficients of variation obtained during
the studies can be seen in Table 1.
For spiked urine the results show that the bias found for
the aliquots stored at either -20 C and -60 C for
20 weeks does not differ significantly from zero
(P [ 0.05), which means that clenbuterol can be regarded
as stable in this matrix. The low CV for clenbuterol con-
centration during storage at -20 C (3.2%) and at -60 C
(3.9%) corroborate this conclusion, because the CV
obtained are rather low and are indeed lower than the
coefficient of variation of the method itself, as estimated
from the daily calibration curves (6.2%, n = 30, in the
concentration range 0.0 to 16.0 ng/ml). These data do not
agree with those from a study undertaken by Gigosos et al.
[17], in which a decrease of clenbuterol concentration was
observed in bovine urine fortified with 10.0 ng/ml and
stored at -15 C for 6 months. It is thus possible to con-
sider the hypothesis that the storage temperature may have
influenced clenbuterol recovery.
Results of linear regression analysis of clenbuterol
concentration in spiked liver during stability studies show
that the bias found for the concentration of clenbuterol of
the stored aliquots, at both -20 C and -60 C, for
20 weeks, differs very significantly from zero for both
temperatures (P \ 0.05). These results demonstrate that
aliquots of bovine liver homogenized and spiked with
10.0 ng/g clenbuterol are unstable when stored for
20 weeks at either of these temperatures. More to the point,
at -20 C, both a decrease in clenbuterol concentration of
about 0.1 ng/g of liver per week and a total decrease of
2.4 ng/g after the 20 weeks of storage were observed. At
-60 C a decrease in clenbuterol concentration of about
0.1 ng/g of liver per week and a total decrease of 2.4 ng/g
after the 20-weeks of storage were also observed. The CV
of clenbuterol concentrations from the beginning to the end
of the experiment obtained at both -20 C and -60 C are
10.5 and 11.1%, respectively. These CV values are higher
than the coefficient of variation of the method estimated
from the calibration curves obtained in intralaboratory
reproducibility conditions (7.7%, n = 30, in the concen-
tration range 0.0 to 16.0 ng/g), which also highlights the
significant lack of stability observed in this study.
This study enables consideration of the hypothesis,
defended by Gude et al. [18], that liver homogenization
activates enzymes which lead to clenbuterol degradation,
and that this degradation takes place even when the liver is
stored frozen, not only at the temperature studied by
Gude et al. (-30 C), but also at -20 C and -60 C.
Clenbuterol degradation may have occurred, however, not
just by activation of enzymes during the grinding proce-
dures prior to sample freezing but also as a result of use of
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Fig. 1 Results from study of the stability of clenbuterol in bovine
urine fortified with 10 ng/ml clenbuterol (UF) and bovine liver
fortified with 10 ng/g clenbuterol (FF) and stored at -20 C and
-60 C (sixfold determination on first day and threefold determina-
tion on each of the subsequent five days, at each temperature)
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the soluble free form (clenbuterol.HCl) with which the
aliquots were spiked. However, the main source of insta-
bility could arise because the water content of the liver was
not reduced to an optimum level with respect to water
activity. This is especially relevant for microbiological
degradation but is also important for degradation because
of enzymatic activity, oxidation, and condensation reac-
tions. Taking several studies into consideration, Linsinger
et al. [19] have concluded that water activities between
0.15 and 0.30 appear to ensure the minimum possible
degradation rate.
As for the possibility of producing ‘‘in house’’ reference
materials consisting of urine or liver spiked with clenbu-
terol in its soluble form (clenbuterol.HCl), this study leads
to different conclusions. The study concludes that such a
possibility exists for urine, because significant stability
(P [ 0.05) of clenbuterol was demonstrated in urine
fortified with 10.0 ng/ml and stored at either -20 C or
-60 C for 20 weeks. In this situation it is possible to
estimate the uncertainty of clenbuterol measurement in
urine at the spiked level, for both temperatures, according
to Linsinger [19]. For the batch of spiked urine stored at
-20 C, for example, the concentration of clenbuterol
(9.54 ng/ml) has an associated uncertainty of 4.30% (or an
uncertainty of 8.6% after multiplication by a coverage
factor of two for a confidence level of approximately 95%,
equivalent to an uncertainty of 0.82 ng/ml).
In contrast, for homogenized liver spiked with clenbu-
terol at 10.0 ng/g it was demonstrated that clenbuterol is
significantly unstable (P \ 0.05) at both -20 C and
-60 C during a 20-week storage period. This instability
demonstrates that it is not possible to produce ‘‘in house’’
reference materials with the matrix liver under the condi-
tions studied. The production of such materials under these
conditions will only be possible at the cost of greater
uncertainty.
Therefore there remains a need for reference materials
comprising bovine liver containing just a single beta-ago-
nist, namely clenbuterol, for validation of screening
methods, particularly for the validation of ELISA-type
tests, for which recovery and cross reactions are extremely
variable. Since these materials are considered indispens-
able for reliability in validation procedures, the official
entities producing certified reference materials, for exam-
ple the Institute for Reference Materials and Measurements
(IRMM) or the National Institute for Public Health and the
Environment (RIVM), are challenged to promote their
production in the form of positive and lyophilized liver, the
stability of which has already been demonstrated. The
future production of certified reference materials contain-
ing only clenbuterol, in matrices of interest, will by an
extremely useful tool for validation of the ELISA-type
screening methods that are already widely used in routine
laboratories.
Acknowledgments The authors are grateful to the Portuguese
Foundation for Science and Technology (POCTI-SFA-8-177), to the
Calouste Gulbenkian Foundation, and to the Services of the Secretary
of Agriculture and Forestry (SRAF) of the Regional Government of
the Autonomous Region of the Azores, for financial support of this
study.
References
1. Council Directive 96/23/EC (1996) Off J Eur Uni L 125:10–32
2. Directive 2003/74/CE (2003) Off J Eur Uni L 262:17–21
3. Martinez-Navarro JF (1990) Lancet 336:1311
4. Garay BJ, Jime´nez JFH, Jime´nez ML, Sebastian MV, Matesanz
JP, Moreno PM, Galiana J (1997) Rev Clin Esp 197(2):92–95
5. Pulce C, Lamaison D, Keck G, Bostvironnois C, Nicolas J,
Descotes J (1991) Vet Hum Toxicol 33(5):480–481
6. Maistro S, Chiesa E, Angeletti R, Brambilla G, (1995) Lancet
346:180
7. Sporano V, Grasso L, Esposito M, Oliviero G, Brambilla G,
Loizzo A (1998) Vet Hum Toxicol 40(3):141–143
8. Brambilla G, Cenci T, Franconi F, Galarini R, Macri A, Rondoni
F, Strozzi M, Loizzo A (2000) Toxicol Lett 114(1–3):47–53
9. Barbosa J, Cruz C, Martins J, Silva JM, Neves C, Alves C, Ramos
F, Silveira MIN (2005) Food Addit Contam 22(6):563–566
10. Shiu TC, Chong WH (2001) Publ Health Epidemiol Bull 10:14–17
11. Cunningham NF, Heitzman RJ (2001) European Commission
EUR 19452/EN, bcr-503
Table 1 Results from study of the stability of clenbuterol in bovine urine fortified with 10 ng/ml clenbuterol (UF) and in bovine liver fortified
with 10 ng/g clenbuterol (FF)
Sample Storage
temperature(C)
Slope Standard
error
of slope
Significance
(p value)
Mean
clenbuterol
(ng/ml)
CV
(%)
Storage
(weeks)
UF -20 -0.009 0.016 0.621 9.54 (n = 21) 4.30 20
-60 -0.027 0.011 0.073 9.59 (n = 21) 3.92 20
FF -20 -0.122 0.011 0.000(4) 9.21 (n = 21) 10.54 20
-60 -0.120 0.026 0.009 9.10 (n = 21) 11.09 20
Simple linear regression analysis was performed, with a Student t test for slope (N - 2 degrees of freedom and 95% confidence, N = 6-days of
analysis). Mean concentration of clenbuterol and the respective coefficient of variation (CV) are given for each storage temperature and each type
of sample for all storage times
Accred Qual Assur (2008) 13:299–304 303
123
12. Gaspar P, van-Vyncht G, Scippo ML, Maghuin-Rogister G,
Kramer GN, Gawlik BM, Linsinger T, Lamberty A, van-Ginkel
LA, Dirscherl C (2002) ISBN 92-894-4657-9-EUR 20526/EN,
bcr-649
13. Montrade MP, le Bizec B, Monteau F, Siliart B, Andre´ F (1993)
Anal Chim Acta 275:253–268
14. Ramos F, Ban˜obre MC, Castilho MC, Silveira MIN (1999) J Liq
Chromatogr Related Technol 22:2307–2320
15. Cristino A, Ramos F, Silveira MIN (2003) J Pharm Biomed Anal
32:311–316
16. Commission Decision 2002/657/EC (2002) Off J Eur Uni
L221:8–36
17. Gigosos PG, Sampayo CF, Abuı´n CF, Sa´ez AC, Belda BIV
(2002) Food Addit Contam 19(11):1010–1014
18. Gude T, Schma¨dicke I, Rahn S, Benesch-Girke L, Hashem A,
PreißA, Ju¨licher B (1996) In: Haagsma N, Ruiter A (eds) Residues
of veterinary drugs in food: Proceedings of the EuroResidue III
conference, pp 157–161
19. Linsinger TPJ, Pauwels J. Van der Veen AMH, Schimmel H,
Lamberty A (2001) Accred Qual Assur 6:20–25
304 Accred Qual Assur (2008) 13:299–304
123
